Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

321
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
321
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

458
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
458
Disorders of Acid-Base Balance01:29

Disorders of Acid-Base Balance

1.2K
The human body maintains a precise pH range of arterial blood between 7.35 and 7.45. Deviations result in either acidosis (pH < 7.35) or alkalosis (pH > 7.45). These conditions are further classified as respiratory or metabolic disorders based on their underlying cause.
Respiratory Acidosis and Alkalosis
Respiratory acidosis occurs due to an increase in the partial pressure of carbon dioxide PCO2 in the blood. It often arises from shallow breathing or impaired gas exchange caused by...
1.2K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

320
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
320
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

967
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
967

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis.

Frontiers in pharmacology·2026
Same author

DNA barcoding-assisted classification of the genus <i>Actias</i> (Lepidoptera: Saturniidae).

Bulletin of entomological research·2026
Same author

The contested association between MASLD and osteoporosis: a narrative review of heterogeneous evidence and modifying factors.

Archives of osteoporosis·2026
Same author

A Review of Hypothyroidism.

JAMA·2026
Same author

A review of rifampicin resistance in mycobacterium tuberculosis: from molecular mechanism to laboratory diagnosis.

Diagnostic microbiology and infectious disease·2025
Same author

Epileptic seizures associated with denosumab.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025

Related Experiment Video

Updated: Sep 14, 2025

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

453

Zoledronic acid-induced acute psychiatric disorder.

Ya-Jun Xiao1, Yu-Yu Zhou1, Yan-Qun Liu2

  • 1Department of Geriatrics, The Third Hospital of Mianyang, Sichuan Mental Health Center, Jiannan Road, Youxian District, Mianyang, Sichuan, China.

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
|July 24, 2025
PubMed
Summary

Zoledronic acid, used for osteoporosis, can rarely cause acute psychiatric disorders. This case highlights the need for vigilance regarding this rare side effect in patients receiving the bisphosphonate drug.

Keywords:
Acute psychiatric disorderAdverse drug reactionZoledronic acid

More Related Videos

A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice
05:28

A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice

Published on: May 15, 2019

22.5K
The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

17.7K

Related Experiment Videos

Last Updated: Sep 14, 2025

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

453
A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice
05:28

A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice

Published on: May 15, 2019

22.5K
The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

17.7K

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Neuroscience

Background:

  • Zoledronic acid is a bisphosphonate commonly prescribed for osteoporosis, hypercalcemia, Paget's disease, and malignant tumors.
  • While acute-phase responses are common adverse effects, psychiatric disorders are infrequently reported.
  • Osteoporosis management often involves bisphosphonate therapy, necessitating awareness of all potential side effects.

Purpose of the Study:

  • To report a rare case of acute psychiatric disorder following zoledronic acid infusion.
  • To emphasize the importance of monitoring for psychiatric adverse reactions in patients treated with zoledronic acid.
  • To contribute to the understanding of the neuropsychiatric effects of bisphosphonate therapy.

Main Methods:

  • A case study approach was employed.
  • Detailed clinical observation and patient history were recorded.
  • Literature review on adverse reactions to zoledronic acid was conducted.

Main Results:

  • An osteoporotic patient developed an acute psychiatric disorder after the first intravenous infusion of zoledronic acid.
  • The patient's psychiatric symptoms emerged shortly after the drug administration.
  • This presentation represents a rare but significant adverse event associated with zoledronic acid.

Conclusions:

  • Acute psychiatric disorder is a rare but possible adverse reaction to zoledronic acid.
  • Clinicians should maintain vigilance for psychiatric symptoms in patients undergoing zoledronic acid treatment.
  • Further research may be warranted to elucidate the mechanisms behind these rare neuropsychiatric effects.